Central Pacific Bank Trust Division Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
otakuyassine3@gmail.com Central Pacific Bank Trust Division cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free...
Pharmaceuticals
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Up 6.1% in December
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) was the recipient of a significant growth...
Short Interest in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Declines By 18.9%
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) was the recipient of a significant drop...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Sells $244,842.48 in Stock
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) CFO Octavio Espinoza sold 2,104 shares of...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Analysts
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have been given a consensus...
Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $49.94
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average...
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $64.67
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned an average recommendation of “Moderate...
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 3.6% Higher – Still a Buy?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) rose 3.6% during mid-day trading on Wednesday...
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1% – Should You Buy?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares shot up 1% during trading on...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given “Market Outperform” Rating at JMP Securities
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “market outperform” rating restated by...
Rhythm Pharmaceuticals’ (RYTM) Buy Rating Reaffirmed at HC Wainwright
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “buy” rating restated by analysts...